<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217265</url>
  </required_header>
  <id_info>
    <org_study_id>letrozole</org_study_id>
    <nct_id>NCT04217265</nct_id>
  </id_info>
  <brief_title>Letrozole Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion</brief_title>
  <official_title>Letrozole Pretreatment With Misoprostol for Induction of Abortion In First-Trimester Missed Miscarriage: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the success rate of letrozole and misoprostol versus misoprostol alone
      for medical termination of first-trimester pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the American college of obstetricians and gynecologists (2005), medical abortion
      is an acceptable alternative for surgical procedures in pregnant women with gestational age
      of less than 49 days based on the last menstrual period

      Oral or vaginal misoprostol causes complete abortion in almost 85% of cases within seven days
      before the 12th week

      letrozole administration with misoprostol raises the rate of complete abortion
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 5, 2020</start_date>
  <completion_date type="Anticipated">April 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete abortion rate</measure>
    <time_frame>9 hours</time_frame>
    <description>Incidence of complete miscarriage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time from induction to abortion</measure>
    <time_frame>9 hours</time_frame>
    <description>induction to abortion time interval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for surgical evacuation of the products of conception</measure>
    <time_frame>9 hours</time_frame>
    <description>how many women will undergo dilatation and curettage after failed medical induction of abortion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Missed Abortion</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets of Letrozole 2.5 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum three doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole then misoprostol</intervention_name>
    <description>total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo then misoprostol</intervention_name>
    <description>placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age less than 64 days gestation (&lt;9 wks).

          -  Hemoglobin &gt;10 g/dL.

          -  BMI between 18.5 kg/m2 and 25 kg/m2.

          -  Missed abortion.

        Exclusion Criteria:

          -  Molar pregnancy.

          -  Fibroid uterus.

          -  Uterine anomalies.

          -  Coagulopathy.

          -  Medical disorder that contraindicate induction of abortion (e.g. heart failure).

          -  Previous attempts for induction of abortion in the current pregnancy.

          -  Allergy to misoprostol or letrozole.

          -  Scared uterus (previous myomectomy, cesarean section, hysterectomy and ruptured
             uterus).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AHMED SAMY</last_name>
    <phone>+201100681167</phone>
    <email>ahmedsamy8233@gmail.com</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>assistant professor obstetrics and gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

